Hypertension Management

First-Line Therapy

The American College of Cardiology/American Heart Association (ACC/AHA) recommends ACE inhibitors or ARBs as preferred initial treatments for primary hypertension without specific compelling indications in patients of any age 1, 2
For patients under 55 years, ACE inhibitors or ARBs are the preferred first-line agents 2
For patients over 55 years and Black patients of any age, Calcium channel blockers are the preferred first-line agents, with Thiazide-like diuretics as an alternative if Calcium channel blockers are not suitable 2
Beta blockers are not recommended as first-line therapy for uncomplicated hypertension due to increased risk of stroke, less favorable cardiovascular outcomes, and potential to lead to dyslipidemia or deterioration of glucose tolerance 1, 3, 2

Beta blockers are recommended for hypertensive patients with specific comorbidities, including heart failure, coronary artery disease/angina, post-myocardial infarction, tachyarrhythmias requiring rate control, hyperkinetic circulation, aortic dissection, or in younger women planning pregnancy 3, 4
Beta blockers are indicated for post-myocardial infarction, reducing mortality, and for angina pectoris/coronary artery disease 3
Beta blockers are used for atrial fibrillation (rate control) and prevention of sudden cardiac death 3

Combination therapy with a second agent from a different class is recommended if blood pressure remains uncontrolled on monotherapy 1
Beta blockers can be effectively combined with other antihypertensive drugs (diuretics or calcium channel blockers) when monotherapy is insufficient, to improve overall cardiovascular outcomes 3
The European Society of Cardiology/European Society of Hypertension (ESC/ESH) and American College of Cardiology/American Heart Association (ACC/AHA) guidelines support the use of combination therapy in hypertension management 5, 3

The European Society of Cardiology suggests that cardioselective beta blockers (metoprolol, bisoprolol, nebivolol) are preferred in patients with respiratory conditions due to their cardioselectivity (β1-selectivity) 3
Carvedilol and nebivolol may offer advantages in certain populations due to their vasodilatory properties, with nebivolol potentially being preferred for patients with diabetes due to favorable effects on glycemic control 3, 6
The American College of Cardiology recommends starting with low doses and titrating gradually to target doses used in clinical trials to avoid inadequate dosing 3, 4
Beta blockers should be tapered gradually to avoid rebound hypertension and tachycardia, and should not be abruptly discontinued 3

Beta blockers are contraindicated in decompensated heart failure requiring intravenous inotropic therapy, second or third-degree AV block without pacemaker, and severe hepatic impairment (for carvedilol) 4, 6
Common mistakes in beta blocker therapy include inadequate dosing, overlooking benefits in COPD, neglecting heart rate reduction benefits, and assuming class effect 3, 4, 7

The American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines support the use of beta blockers in hypertension management, with a strength of evidence ranging from moderate to high 3, 4, 7, 6
The Hypertension guideline recommends beta blockers for hypertension with specific comorbidities, heart failure with reduced ejection fraction, post-myocardial infarction, angina pectoris, and certain arrhythmias 3, 4